PDCD1 and non-small cell lung carcinoma: Monoclonal antibodies targeting the PD-1 (programmed cell death protein 1)/PD-L1 (programmed death-ligand 1) immune checkpoint axis, including atezolizumab, cemiplimab-rwlc, durvalumab, ipilimumab, nivolumab, pembrolizumab and tremelimumab, are used for the treatment of NSCLC.